Skip to content
Subscriber Only

Glaxo to Invest $360 Million in Three U.K. Manufacturing Sites

  • Company will boost production of respiratory drugs, biologics
  • Majority of products will be exported to global markets
Video player cover image

GlaxoSmithKline CEO: Strong Currency Tailwind Effect

GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, will invest 275 million pounds ($360 million) at manufacturing sites to boost production of respiratory and biologic medicines, mostly for export.

The investments will be spread across three U.K. sites: Barnard Castle and Ware in England, and Montrose in Scotland, the company said Wednesday in a statement. The money also will lead to the creation of new U.K.-based jobs at Glaxo.